FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2741552886> ?p ?o ?g. }

• W2741552886 endingPage "70440" @default.
• W2741552886 startingPage "70431" @default.
• W2741552886 abstract "// Jongmi Lee 1 , Ki Hyun Park 2 , Ji Hyeong Ryu 2 , Hyun Jin Bae 2 , Aeran Choi 1 , Hyeyoung Lee 1, 3 , Jihyang Lim 1 , Kyungja Han 1 , Cho Hyun Park 4 , Eun Sun Jung 5 and Eun-Jee Oh 1 1 Department of Laboratory Medicine, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea 2 Department of Biomedical Science, Graduate School, The Catholic University of Korea, Seoul, Korea 3 SamKwang Medical Laboratories, Seoul, Korea 4 Division of Gastrointestinal Surgery, Department of Surgery, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea 5 Department of Hospital Pathology, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea Correspondence to: Eun-Jee Oh, email: ejoh@catholic.ac.kr Keywords: natural killer cell activity, interferon-gamma, diagnostic marker, gastric cancer Received: May 10, 2017      Accepted: June 28, 2017      Published: July 31, 2017 ABSTRACT Background/Aim: Decreased Natural killer cell activity (NKA) for interferon-gamma production (NKA-IFNγ) has been reported in cancer patients. The aim of this study was to determine the diagnostic performance of NKA-IFNγ for gastric cancer (GC). Results: NKA-IFNγ levels were decreased in 261 GC patients with all stages of tumor compared to those in 48 healthy donors ( P < 0.001), and lower levels of NKA-IFNγ were associated with higher GC stages. NKA-IFNγ levels were also associated with clinicopathological parameters including tumor size, depth of invasion, and lymph node metastasis. NKA-INFγ assay had better diagnostic value (AUC = 0.822) compared to serum CEA (0.624) or CA19-9 assay (0.566) ( P < 0.001). Using different cut-off levels, serum CEA and CA19-9 showed sensitivities of 6.1-14.2% and 4.2-28.0%, respectively, which were much lower than that of NKA-IFNγ (55.6-66.7%). Methods: This study included 261 patients with newly diagnosed GC and 48 healthy donors. NKA for IFNγ was determined by enzyme immunoassay after incubation of whole blood, and diagnostic performance was evaluated. Conclusions: NK cell activities for IFNγ production could be used as a supportive non-invasive tumor marker for GC diagnosis." @default.
• W2741552886 created "2017-08-08" @default.
• W2741552886 creator A5007291907 @default.
• W2741552886 creator A5009770843 @default.
• W2741552886 creator A5028754045 @default.
• W2741552886 creator A5043846826 @default.
• W2741552886 creator A5044748271 @default.
• W2741552886 creator A5053600900 @default.
• W2741552886 creator A5063419287 @default.
• W2741552886 creator A5071452667 @default.
• W2741552886 creator A5075108989 @default.
• W2741552886 creator A5078925410 @default.
• W2741552886 creator A5087339024 @default.
• W2741552886 date "2017-07-31" @default.
• W2741552886 modified "2023-10-11" @default.
• W2741552886 title "Natural killer cell activity for IFN-gamma production as a supportive diagnostic marker for gastric cancer" @default.
• W2741552886 cites W1518342882 @default.
• W2741552886 cites W1534916753 @default.
• W2741552886 cites W1661892624 @default.
• W2741552886 cites W1887727761 @default.
• W2741552886 cites W1965591985 @default.
• W2741552886 cites W1966224577 @default.
• W2741552886 cites W1967674445 @default.
• W2741552886 cites W1973658130 @default.
• W2741552886 cites W1986897680 @default.
• W2741552886 cites W2011115262 @default.
• W2741552886 cites W2017447566 @default.
• W2741552886 cites W2019069555 @default.
• W2741552886 cites W2047028937 @default.
• W2741552886 cites W2047276834 @default.
• W2741552886 cites W2059220359 @default.
• W2741552886 cites W2066245403 @default.
• W2741552886 cites W2067371565 @default.
• W2741552886 cites W2071568295 @default.
• W2741552886 cites W2075464097 @default.
• W2741552886 cites W2086156388 @default.
• W2741552886 cites W2097610703 @default.
• W2741552886 cites W2146313292 @default.
• W2741552886 cites W2155349194 @default.
• W2741552886 cites W2160720185 @default.
• W2741552886 cites W2162676322 @default.
• W2741552886 cites W2261860746 @default.
• W2741552886 cites W2303309927 @default.
• W2741552886 cites W2345158788 @default.
• W2741552886 cites W2406154073 @default.
• W2741552886 cites W2417735069 @default.
• W2741552886 cites W2433275279 @default.
• W2741552886 cites W2463722124 @default.
• W2741552886 cites W2465587303 @default.
• W2741552886 cites W2509966050 @default.
• W2741552886 cites W2519983801 @default.
• W2741552886 cites W2529369867 @default.
• W2741552886 cites W2583982957 @default.
• W2741552886 cites W4285719527 @default.
• W2741552886 cites W804513914 @default.
• W2741552886 doi "https://doi.org/10.18632/oncotarget.19712" @default.
• W2741552886 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5642566" @default.
• W2741552886 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29050291" @default.
• W2741552886 hasPublicationYear "2017" @default.
• W2741552886 type Work @default.
• W2741552886 sameAs 2741552886 @default.
• W2741552886 citedByCount "43" @default.
• W2741552886 countsByYear W27415528862018 @default.
• W2741552886 countsByYear W27415528862019 @default.
• W2741552886 countsByYear W27415528862020 @default.
• W2741552886 countsByYear W27415528862021 @default.
• W2741552886 countsByYear W27415528862022 @default.
• W2741552886 countsByYear W27415528862023 @default.
• W2741552886 crossrefType "journal-article" @default.
• W2741552886 hasAuthorship W2741552886A5007291907 @default.
• W2741552886 hasAuthorship W2741552886A5009770843 @default.
• W2741552886 hasAuthorship W2741552886A5028754045 @default.
• W2741552886 hasAuthorship W2741552886A5043846826 @default.
• W2741552886 hasAuthorship W2741552886A5044748271 @default.
• W2741552886 hasAuthorship W2741552886A5053600900 @default.
• W2741552886 hasAuthorship W2741552886A5063419287 @default.
• W2741552886 hasAuthorship W2741552886A5071452667 @default.
• W2741552886 hasAuthorship W2741552886A5075108989 @default.
• W2741552886 hasAuthorship W2741552886A5078925410 @default.
• W2741552886 hasAuthorship W2741552886A5087339024 @default.
• W2741552886 hasBestOaLocation W27415528861 @default.
• W2741552886 hasConcept C121608353 @default.
• W2741552886 hasConcept C126322002 @default.
• W2741552886 hasConcept C556039675 @default.
• W2741552886 hasConcept C71924100 @default.
• W2741552886 hasConceptScore W2741552886C121608353 @default.
• W2741552886 hasConceptScore W2741552886C126322002 @default.
• W2741552886 hasConceptScore W2741552886C556039675 @default.
• W2741552886 hasConceptScore W2741552886C71924100 @default.
• W2741552886 hasIssue "41" @default.
• W2741552886 hasLocation W27415528861 @default.
• W2741552886 hasLocation W27415528862 @default.
• W2741552886 hasLocation W27415528863 @default.
• W2741552886 hasLocation W27415528864 @default.
• W2741552886 hasOpenAccess W2741552886 @default.
• W2741552886 hasPrimaryLocation W27415528861 @default.
• W2741552886 hasRelatedWork W1506200166 @default.
• W2741552886 hasRelatedWork W1995515455 @default.

• next